KR20130047040A - Composition for skin whitening containing chelidonium majus extracts and trihydroxyisoflavones - Google Patents
Composition for skin whitening containing chelidonium majus extracts and trihydroxyisoflavones Download PDFInfo
- Publication number
- KR20130047040A KR20130047040A KR1020110111810A KR20110111810A KR20130047040A KR 20130047040 A KR20130047040 A KR 20130047040A KR 1020110111810 A KR1020110111810 A KR 1020110111810A KR 20110111810 A KR20110111810 A KR 20110111810A KR 20130047040 A KR20130047040 A KR 20130047040A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- genus
- skin whitening
- trihydroxy
- extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 230000002087 whitening effect Effects 0.000 title claims abstract description 45
- 239000000284 extract Substances 0.000 title claims description 65
- 241001233914 Chelidonium majus Species 0.000 title description 3
- DZKZCXUIXLRBSY-UHFFFAOYSA-N Oc1ccc2oc(O)c(-c3ccccc3)c(=O)c2c1O Chemical class Oc1ccc2oc(O)c(-c3ccccc3)c(=O)c2c1O DZKZCXUIXLRBSY-UHFFFAOYSA-N 0.000 title 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 52
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 52
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 35
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 235000007240 daidzein Nutrition 0.000 claims abstract description 4
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 claims abstract 2
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 claims abstract 2
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 claims abstract 2
- DDKGKOOLFLYZDL-UHFFFAOYSA-N 3',4',7-trihydroxyisoflavone Chemical group C=1C(O)=CC=C(C2=O)C=1OC=C2C1=CC=C(O)C(O)=C1 DDKGKOOLFLYZDL-UHFFFAOYSA-N 0.000 claims description 40
- 244000005700 microbiome Species 0.000 claims description 18
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 235000021374 legumes Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 9
- 230000008099 melanin synthesis Effects 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 6
- 230000019612 pigmentation Effects 0.000 claims description 5
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 4
- 241000235575 Mortierella Species 0.000 claims description 4
- 241000228212 Aspergillus Species 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241001467578 Microbacterium Species 0.000 claims description 2
- 241000228143 Penicillium Species 0.000 claims description 2
- 241000235402 Rhizomucor Species 0.000 claims description 2
- 241000235527 Rhizopus Species 0.000 claims description 2
- 241000316848 Rhodococcus <scale insect> Species 0.000 claims description 2
- 241000228341 Talaromyces Species 0.000 claims description 2
- 102000004357 Transferases Human genes 0.000 claims description 2
- 108090000992 Transferases Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 238000005238 degreasing Methods 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 abstract description 50
- 210000004927 skin cell Anatomy 0.000 abstract description 4
- 229940002385 chelidonium majus extract Drugs 0.000 abstract 2
- 241000220485 Fabaceae Species 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000003061 melanogenesis Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 16
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 16
- -1 foundation Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical group CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000002537 cosmetic Substances 0.000 description 10
- 239000000049 pigment Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 241000237502 Ostreidae Species 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000006210 lotion Substances 0.000 description 9
- 235000020636 oyster Nutrition 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000006071 cream Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000013538 functional additive Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000004694 pigment cell Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000020712 soy bean extract Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- BWSWZBCSFZAYOB-CABCVRRESA-N (2s,4r)-1-dodecanoyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1C(O)=O BWSWZBCSFZAYOB-CABCVRRESA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241001412143 Eriogonum corymbosum Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 244000187664 Nerium oleander Species 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000010476 Respiratory Paralysis Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 피부 미백용 조성물 및 그 제조방법에 관한 것이다.The present invention relates to a composition for skin whitening and a method for producing the same.
사람의 피부색을 결정하는 데는 여러가지 요인들이 관여하는데, 그 중에서도 멜라닌 색소를 만드는 멜라노사이트(melanocyte)의 활동성, 혈관의 분포, 피부의 두께 및 카로티노이드, 빌리루빈 등의 인체 내외의 색소 함유 유무 등의 요인들이 중요하다. Many factors are involved in determining the skin color of humans, including the activity of melanocytes (melanocytes) that make melanin pigment, the distribution of blood vessels, the thickness of skin and the presence or absence of pigments in the body such as carotenoids and bilirubin. It is important.
이중 특히 가장 중요한 요인은 인체 내의 멜라노사이트에서 타이로시나제 등의 여러 효소가 작용하여 생성되는 멜라닌이라는 흑색 색소이다. 이 멜라닌 색소의 형성에는 유전적 요인, 호르몬 분비, 스트레스 등과 관련된 생리적 요인 및 자외선 조사 등과 같은 환경적 요인 등이 영향을 미친다. Especially, the most important factor is melanin, a melanin pigment produced by the action of various enzymes such as tyrosinase in melanocytes in the human body. The formation of melanin pigment affects genetic factors, hormonal secretion, physiological factors such as stress, and environmental factors such as ultraviolet irradiation.
신체 피부의 멜라닌 세포에서 생성되는 멜라닌 색소는 검은 색소와 단백질의 복합체 형태를 갖는 페놀계 고분자 물질로서, 태양으로부터 조사되는 자외선을 차단하여 진피 이하의 피부기관을 보호해주는 동시에 피부 생체 내에 생겨난 자유 라디칼 등을 잡아주는 등 피부 내 단백질과 유전자들을 보호해주는 유용한 역할을 담당한다. The melanin pigment produced in melanocytes of body skin is a phenolic polymer substance having a complex form of black pigment and protein. It protects the subcutaneous skin organs by blocking ultraviolet rays irradiated from the sun, and at the same time, free radicals And protects proteins and genes in the skin.
이와 같이 피부 내, 외부의 스트레스적 자극에 의해 생겨난 멜라닌은, 스트레스가 사라져도 피부 각질화를 통해서 외부로 배출되기 전까지는 없어지지 않는 안정한 물질이다. 그러나 멜라닌이 필요 이상으로 많이 생기게 되면 기미나 주근깨, 점 등과 같은 과색소 침착증을 유발하여 미용상으로 좋지 않은 결과를 가져오게 된다. 또한, 레저 인구의 증가로 외부에서 활동하는 것을 즐기는 사람들이 많아지면서 자외선에 의한 멜라닌 색소 침착을 막고자 하는 요구가 늘어나게 되었다.Melanin, which is produced by stress stimuli inside and outside of the skin, is a stable substance that does not disappear until the skin is excreted through skin keratinization even if the stress disappears. However, when melanin is produced more than necessary, it induces hypercholesterolemia such as spots, freckles, and dots, resulting in poor cosmetic results. In addition, as the leisure population increases, the number of people who enjoy being active outside increases the demand to prevent melanin pigmentation caused by ultraviolet rays.
이와 같은 요구에 부응하여 종전부터 아스코르빈산, 코지산, 알부틴, 하이드로퀴논, 글루타치온 또는 이들의 유도체, 또는 타이로시나제 저해활성을 가진 물질들을 화장료나 의약품에 배합하여 사용하여 왔으나, 이들의 불충분한 미백 효과, 피부에 대한 안전성 문제, 화장료에 배합시 나타나는 제형 및 안정성의 문제 등으로 인해 그 사용이 제한되고 있다.In response to this demand, ascorbic acid, kojic acid, arbutin, hydroquinone, glutathione or derivatives thereof, or substances having tyrosinase inhibitory activity have been used in combination with cosmetics or pharmaceuticals, but they are insufficient. Its use has been limited due to its whitening effect, safety issues with the skin, formulation and stability problems when formulated in cosmetics, and the like.
본 발명의 목적은 우수한 미백 효과를 나타내는 피부 미백용 조성물 및 그 제조방법을 제공하는 데 있다.It is an object of the present invention to provide a composition for skin whitening and a method for producing the same, which exhibits an excellent whitening effect.
상기 목적을 달성하기 위하여, 본 발명은 유효성분으로서 백굴채 추출물 및 트리히드록시 이소플라본 (trihydroxy isoflavone)을 함유하는 피부 미백용 조성물을 제공한다. In order to achieve the above object, the present invention provides a composition for skin whitening containing baekchulchae extract and trihydroxy isoflavone as an active ingredient.
아울러, 본 발명은 다이드진 (daidzin) 또는 다이드자인 (daidzein)을 함유하는 콩과식물에 미생물을 처리하여 트리히드록시 이소플라본 (trihydroxy isoflavone)을 제조하는 것을 포함하는 피부 미백용 조성물의 제조방법을 제공한다.In addition, the present invention is a method for producing a composition for skin whitening comprising the production of trihydroxy isoflavone by treating microorganisms in legumes containing didzin or daidzein To provide.
본 발명에 의한 백굴채 추출물 및 트리히드록시 이소플라본을 유효성분으로 함유하는 피부 미백용 조성물은, 피부 안전성을 유지하면서도 피부 세포 사멸 억제, 멜라닌 생성 억제, 및 자외선(ultraviolet rays; UV)에 의해 생성된 색소 침착 개선에 따라 우수한 피부 미백 효과를 나타내므로, 피부 미백용 조성물로서 유용하게 사용될 수 있다.The composition for skin whitening containing the white bran extract and the trihydroxy isoflavone according to the present invention as an active ingredient is produced by inhibiting skin cell death, inhibiting melanin production, and ultraviolet rays while maintaining skin safety. As a result of improved pigmentation, it shows an excellent skin whitening effect, and thus can be usefully used as a composition for skin whitening.
본 발명은 일 관점에서, 유효성분으로서 백굴채 추출물 및 트리히드록시 이소플라본 (trihydroxy isoflavone)을 함유하는 피부 미백용 조성물에 관한 것이다. The present invention, in one aspect, relates to a composition for skin whitening containing baekgulchae extract and trihydroxy isoflavone as an active ingredient.
백굴채는 양귀비과의 애기똥풀 (Chelidonium majus)의 지상부를 의미한다. 백굴채 추출물은 진통(鎭痛)작용이 있으며 기침을 그치게 하고 위(胃)가 아프거나 황달(黃疸), 뱀이나 벌레에 물린 데에 쓰이는 약재로 알려져 있으나, 그 자체에 독이 있어 과용하면 경련, 점막의 염증, 요혈, 변혈, 눈동자의 수축, 마비, 혼수상태, 호흡마비가 올 수 있다. 본 발명의 일 관점에 있어서, 백굴채 추출물은 애기똥풀의 지상부에 있는 잎, 꽃, 줄기, 가지 및 껍질 등을 포함하는 다양한 기관의 전체 또는 부분으로부터 추출하여 얻은 것을 의미한다. 본 발명의 백굴채 추출물은 당업계에 공지된 통상의 방법에 따라, 즉, 통상적인 온도와 압력의 조건하에서, 통상적인 용매를 사용하여 제조될 수 있다. 백굴채를 분쇄하여 열수로 추출하거나, 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 이용한 추출 또는 크로마토그래피법에 의하여 백굴채 추출물을 제조할 수 있으나, 이에 제한되는 것은 아니다. White oysters in the genus Papaveraceae ( Chelidonium majus ) means above ground. Baekgulchae extract has analgesic effect and stops coughing and is known as a medicine used for sore stomach, jaundice, snakes, or insect bites. Inflammation of the mucous membranes, bleeding, hemorrhage, constriction of the eyes, paralysis, coma, respiratory paralysis may occur. In one aspect of the present invention, baekchulchae extract means that it is obtained by extracting from the whole or part of various organs, including leaves, flowers, stems, branches and bark in the ground part of celandine. The white bran extract of the present invention may be prepared according to conventional methods known in the art, that is, using a conventional solvent, under conditions of conventional temperature and pressure. White bran extract may be pulverized and extracted with hot water, or white bran extract may be prepared by extraction or chromatography using an ultrafiltration membrane having a constant molecular weight cut-off value, but is not limited thereto.
본 발명의 일 관점에 있어서, 트리히드록시 이소플라본 (trihydroxy isoflavone)은 3개의 히드록시 (hydroxy) 그룹을 포함하는 이소플라본을 의미한다. 이소플라본은 여성호르몬인 에스트로겐과 유사하여 에스트로겐 분비를 유도하는 물질로 식물성 에스트로겐(phytoestrogen)이라고도 불리운다. In one aspect of the invention, trihydroxy isoflavone means an isoflavone comprising three hydroxy groups. Isoflavones are similar to the female hormone estrogen and induce estrogen secretion, also called phytoestrogen.
본 발명의 일 관점인 피부 미백용 조성물에 있어서, 상기 트리히드록시 이소플라본은 3',4',7-트리히드록시 이소플라본 (3',4',7-trihydroxy isoflavone)일 수 있다. 3',4',7-트리히드록시 이소플라본은 하기 화학식 1과 같이 표현될 수 있다.In the composition for skin whitening which is an aspect of the present invention, the trihydroxy isoflavone may be 3 ', 4', 7-trihydroxy isoflavone (3 ', 4', 7-trihydroxy isoflavone). 3 ', 4', 7-trihydroxy isoflavones may be represented by the following formula (1).
본 발명의 일 관점인 피부 미백용 조성물에 있어서, 상기 트리히드록시 이소플라본 (trihydroxy isoflavone)은 콩과식물에 함유된 다이드진 (daidzin) 또는 다이드자인 (daidzein)으로부터 유래된 것을 포함할 수 있다. 다이드진은 하기 화학식 2와 같이 표현될 수 있고, 다이드자인은 하기 화학식 3과 같이 표현될 수 있다. In a composition for skin whitening, which is an aspect of the present invention, the trihydroxy isoflavone may include one derived from diedzin or diedzein contained in legumes. . Didezin may be represented by the following formula (2), and dydazine may be represented by the following formula (3).
본 발명의 일 관점인 피부 미백용 조성물에 있어서, 백굴채 추출물 및 트리히드록시 이소플라본의 함량은 조성물 총 중량에 대하여 0.0001 중량% 내지 10 중량% 함유될 수 있다. 백굴채 추출물 및 트리히드록시 이소플라본의 함유량이 조성물 총 중량에 대하여 0.0001 중량% 미만으로 함유되면 미백 효과가 충분히 나타나지 않고, 10 중량%를 초과하여 함유되면 함량 증가에 비하여 미백 효과의 증가가 크지 않다. 상기와 같은 관점에 의하여, 본 발명의 일 관점에 있어서, 백굴채 추출물 및 트리히드록시 이소플라본의 함량은 0.01 중량% 내지 10 중량%,0.1 중량% 내지 10 중량% 또는 1 중량% 내지 10 중량%일 수 있다.In the composition for skin whitening, which is an aspect of the present invention, the content of Baekchulchae extract and trihydroxy isoflavone may be contained in 0.0001 wt% to 10 wt% based on the total weight of the composition. The content of white oyster extract and trihydroxy isoflavone is less than 0.0001% by weight based on the total weight of the composition, the whitening effect does not appear sufficiently. . In view of the above, in one aspect of the present invention, the content of Baekchulchae extract and trihydroxy isoflavones is 0.01 to 10% by weight, 0.1 to 10% by weight or 1 to 10% by weight Can be.
본 발명의 일 관점인 피부 미백용 조성물에 있어서, 상기 백굴채 추출물 대 트리히드록시 이소플라본 (trihydroxy isoflavone)의 중량비는 1:10 내지 100:1일 수 있다. 상기 범위 외의 중량비를 가지는 경우, 백굴채 추출물 또는 트리히드록시 이소플라본 일방의 함량이 너무 적게 되어 시너지 효과를 얻는 것이 어렵다. 상기와 같은 관점에 의하여, 본 발명의 일 관점에 있어서, 백굴채 추출물 대 트리히드록시 이소플라본 (trihydroxy isoflavone)의 중량비는 1:5 내지 90:1, 1:1 내지 80:1, 10:1 내지 70:1, 20:1 내지 70:1, 30:1 내지 70:1 또는 40:1 내지 70:1일 수 있다.In the composition for skin whitening, which is an aspect of the present invention, the weight ratio of the white bran extract to trihydroxy isoflavone may be 1:10 to 100: 1. When having a weight ratio outside the above range, it is difficult to obtain synergistic effect because the content of one of the baekgulchae extract or trihydroxy isoflavone is too small. In view of the above, in one aspect of the present invention, the weight ratio of white bran extract to trihydroxy isoflavone is 1: 5 to 90: 1, 1: 1 to 80: 1, 10: 1 To 70: 1, 20: 1 to 70: 1, 30: 1 to 70: 1 or 40: 1 to 70: 1.
본 발명의 일 관점인 피부 미백용 조성물은 멜라닌 생성 억제능을 가질 수 있고, 더불어, 본 발명의 일 관점인 피부 미백용 조성물은 색소 침착 개선능을 가질 수 있다. The skin whitening composition of one aspect of the present invention may have melanin production inhibiting ability, and in addition, the composition for skin whitening of one aspect of the present invention may have pigmentation improving ability.
본 발명의 일 관점인 피부 미백용 조성물은 약학 조성물 또는 화장료 조성물로 이용될 수 있다.Skin whitening composition of one aspect of the present invention can be used as a pharmaceutical composition or cosmetic composition.
상기 피부 미백용 약학 조성물에는 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 약제학적 보조제 및 기타 치료적으로 유용한 물질을 추가로 함유할 수 있으며, 통상적인 방법에 따라 다양한 비경구 투여 형태로 제형화할 수 있다. 비경구 투여 형태로 경피 투여형 제형일 수 있으며, 예를 들어 로션, 연고, 겔, 크림, 패취 또는 분무제 제형일 수 있으나, 이에 제한되는 것은 아니다. 상기 유효 성분의 투여량 결정은 당업자의 수준 내에 있으며, 약물의 1일 투여 용량은 투여하고자 하는 대상의 발병 시기, 연령, 건강상태, 합병증 등의 다양한 요인에 따라 달라지지만, 성인을 기준으로 할 때 일반적으로는 상기 조성물 1㎍/kg 내지 200mg/kg, 바람직하게는 50㎍/kg 내지 50mg/kg을 1일 1 내지 3회 분할하여 투여할 수 있으며, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것이 아니다.The pharmaceutical composition for skin whitening may further contain pharmaceutical supplements such as preservatives, stabilizers, hydrating or emulsifiers, salts and / or buffers for the control of osmotic pressure, and other therapeutically useful substances. Accordingly, it can be formulated into various parenteral dosage forms. Parenteral dosage forms, and may be, for example, but not limited to lotions, ointments, gels, creams, patches or spray formulations. Determination of the dosage of the active ingredient is within the level of those skilled in the art, and the daily dosage of the drug depends on various factors such as the onset of the subject to be administered, age, health condition, complications, etc. In general, 1 μg / kg to 200 mg / kg of the composition, preferably 50 μg / kg to 50 mg / kg, may be administered by dividing 1 to 3 times a day, and the dosage may be administered by any method of the present invention. It is not intended to limit the scope.
상기 피부 미백용 화장료 조성물은 제형이 특별히 한정되지 않으며, 목적하는 바에 따라 적절히 선택할 수 있다. 예를 들어, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저로 이루어진 군으로부터 선택된 어느 하나 이상의 제형으로 제조될 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition for skin whitening is not particularly limited in formulation, and may be appropriately selected as desired. For example, skin lotion, skin softener, skin toner, astringent, lotion, milky lotion, moisturizing lotion, nutrition lotion, massage cream, nutritional cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing But the present invention is not limited thereto, and may be manufactured by any one or more formulations selected from the group consisting of a foam, a cleansing lotion, a cleansing cream, a body lotion and a body cleanser.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, and especially in the case of spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.In the case of the solution or emulsion of the present invention, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolenic derivatives or ethoxylated glycerol fatty acid esters.
상기 유효 성분의 함량은 특별히 제한되지 않으나, 조성물 총 중량을 기준으로 0.0001 내지 10 중량%로 포함될 수 있다. 상기 유효 성분이 상기 함량을 만족하는 경우 부작용 없이 우수한 효능을 나타낼 수 있다.The content of the active ingredient is not particularly limited, but may be included as 0.0001 to 10% by weight based on the total weight of the composition. When the active ingredient satisfies the content, it may exhibit excellent efficacy without side effects.
상기 화장료 조성물에는 상기 제조된 백굴채 추출물 및 트리히드록시 이소플라본 이외에 기능성 첨가물 및 일반적인 화장료 조성물에 포함되는 성분이 추가로 포함될 수 있다. 상기 기능성 첨가물로는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 성분을 포함할 수 있다.The cosmetic composition may further include functional additives and components included in the general cosmetic composition in addition to the baekgulchae extract and trihydroxy isoflavones prepared above. The functional additives may include water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.
본 발명의 화장료 조성물에는 더불어, 상기 기능성 첨가물과 더불어 필요에 따라 일반적인 화장료 조성물에 포함되는 성분을 배합할 수 있다. 이외에 포함되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.In addition to the functional additive, the cosmetic composition of the present invention may be blended with components contained in a general cosmetic composition as necessary. In addition to the other components included, oils and fats, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, blood circulation And accelerators, cooling agents, limiting agents, purified water, and the like.
본 발명은 다른 일 관점에서 트리히드록시 이소플라본 (trihydroxy isoflavone)은 다이드진 (daidzin) 또는 다이드자인 (daidzein)을 함유하는 콩과식물과 미생물과의 반응으로 제조되는, 피부 미백용 조성물의 제조방법에 관한 것이다. According to another aspect of the present invention, trihydroxy isoflavone is prepared by reacting legumes containing diedzin or daidzein with microorganisms, and the composition for skin whitening. It is about a method.
본 발명의 일 관점인 피부 미백용 조성물의 제조방법에 있어서, 상기 트리히드록시 이소플라본 (trihydroxy isoflavone)은 3',4',7-트리히드록시 이소플라본일 수 있다.In the method for preparing a composition for skin whitening, which is an aspect of the present invention, the trihydroxy isoflavone may be 3 ', 4', 7-trihydroxy isoflavone.
본 발명의 일 관점인 피부 미백용 조성물의 제조방법에 있어서, 상기 미생물은 엑소 당결합 분해효소 및 히드록시기 전달효소의 생산능을 포함할 수 있다. 본 발명의 일 관점에 있어서, 콩과식물로부터 추출한 다이드진이 미생물의 엑소 당결합 분해효소에 의하여 당이 분해되면, 다이드자인이 생성되고, 미생물의 히드록시기 전달효소가 다이드자인에 히드록시기를 전달하면 트리히드록시 이소플라본을 제조할 수 있다. 아울러, 콩과식물로부터 추출한 다이드자인은 미생물의 히드록시기 전달효소에 의하여 트리히드록시 이소플라본으로 변환될 수 있다. In the method for producing a composition for skin whitening, which is an aspect of the present invention, the microorganism may include a production capacity of an exo sugar-binding enzyme and a hydroxyl group transferase. In one aspect of the present invention, when the sugar is decomposed by the exo-glucose degrading enzyme of the microorganism Dydjin extracted from legumes, the dyedzain is produced, when the hydroxyl group transfer enzyme of the microorganism delivers a hydroxyl group to the Hydroxy isoflavones can be prepared. In addition, DyedZine extracted from legumes can be converted to trihydroxy isoflavones by the hydroxyl group transfer enzyme of the microorganism.
본 발명의 일 관점인 피부 미백용 조성물의 제조방법에 있어서, 상기 미생물은 아스퍼질러스(Aspergillus)속, 바실러스(Bacillus)속, 페니실리움(Penicillium)속, 리조푸스(Rhizopus)속, 리조무코르(Rhizomucor)속, 탈라로마이세스(Talaromyces)속, 비피도박테리움(Bifidobacterium)속, 모르티에렐라(Mortierella)속, 크립토코커스(Cryptococcus)속 및 마이크로박테리움(Microbacterium)속으로 이루어진 군으로부터 선택된 하나 이상의 미생물을 포함할 수 있다. In the method for producing a composition for skin whitening, which is an aspect of the present invention, the microorganism is Genus Aspergillus , Genus Bacillus , Genus Penicillium , Genus Rhizopus , Genus Rizomu cor (Rhizomucor), An in Tallahassee My process (Talaromyces) in, from Bifidobacterium (Bifidobacterium) genus Mortierella (Mortierella) genus, Cryptococcus Rhodococcus (Cryptococcus) in and micro tumefaciens group consisting of genus (Microbacterium) It may include one or more microorganisms selected.
본 발명의 일 관점인 피부 미백용 조성물의 제조방법에 있어서, 상기 콩과식물은 대두를 포함할 수 있다. In the method for preparing a composition for skin whitening, which is an aspect of the present invention, the legume may include soybean.
본 발명의 일 관점인 피부 미백용 조성물의 제조방법에 있어서, 상기 트리히드록시 이소플라본 (trihydroxy isoflavone)을 제조하는 것은, 콩과식물을 탈지하는 단계; 탈지된 콩과식물을 용매에 넣고 추출물을 얻는 단계; 및 상기 추출물에 미생물을 접종하고 배양하는 단계를 포함하는, 피부 미백용 조성물의 제조방법을 제공한다. 이하, 상기 트리히드록시 이소플라본 (trihydroxy isoflavone)의 제조단계를 상세히 설명한다.In the method for producing a composition for skin whitening, which is an aspect of the present invention, preparing the trihydroxy isoflavone includes: degreasing legumes; Putting the defatted legumes in a solvent to obtain an extract; And inoculating and culturing the microorganisms in the extract, it provides a method for producing a skin whitening composition. Hereinafter, the manufacturing steps of the trihydroxy isoflavone will be described in detail.
먼저, 대두 또는 대두 배아에 약 1배 내지 6배, 바람직하게는 약 3배의 물 또는 에탄올, 메탄올, 부탄올, 에테르, 에틸아세테이트 및 클로로포름을 포함하는 군으로부터 선택된 하나 이상의 유기용매 또는 이들 유기용매와 물과의 혼합용매를 넣는다. 그 후, 상온에서 1회 내지 5회 교반하면서 추출하여 탈지시킨 다음, 탈지된 식물에 약 1배 내지 8배, 바람직하게는 약4 배의 물 또는 상기 유기용매를 넣고, 1회 내지 5회 환류 추출한 후, 10℃ 내지 20℃에서 1일 내지 3일간 침적시킨 후, 여과와 원심분리를 통하여 잔사와 여액을 분리한다. 분리된 여액을 감압농축하여 얻은 엑기스를 물에 현탁한 후, 에테르 등을 이용하여 색소를 제거한 다음, 수층을 상기 유기용매를 사용하여 1 내지 5회 추출한 후, 수득한 유기 용매층을 감압농축하여 유기용매 엑기스를 얻는다. 이를 소량의 메탄올 등에 녹인 후, 대량의 에틸아세테이트 등을 추가하여 생성된 침전물을 건조시켜, 다이드진 또는 다이드제인을 함유하는 추출물을 수득할 수 있다. First, about 1 to 6 times, preferably about 3 times, water or one or more organic solvents selected from the group comprising ethanol, methanol, butanol, ether, ethyl acetate and chloroform or soybeans or soybean embryos; Add a solvent mixed with water. Thereafter, the mixture is extracted and degreased with stirring once to five times at room temperature, and then about 1 to 8 times, preferably about 4 times, water or the organic solvent is added to the degreased plant, and refluxed 1 to 5 times. After extraction, the mixture was deposited at 10 ° C. to 20 ° C. for 1 to 3 days, and then the residue and the filtrate were separated by filtration and centrifugation. The extract obtained by concentrating the separated filtrate under reduced pressure was suspended in water, the pigment was removed using ether, etc., the aqueous layer was extracted 1 to 5 times using the organic solvent, and the obtained organic solvent layer was concentrated under reduced pressure. Obtain an organic solvent extract. After dissolving this in a small amount of methanol or the like, a large amount of ethyl acetate or the like is added to dry the resulting precipitate, thereby obtaining an extract containing dydzin or dydzein.
다이드진 또는 다이드제인을 함유하는 추출물을 5 내지 10배, 바람직하게는 약 10배의 이온수에 용해시킨 후 121℃에서 30분간 멸균하여 30 ℃로 냉각한 후 미리 배양된 미생물을 액체량 대비 5~10% 로 접종하여 30℃에서 2 내지 5일 배양 시킨 후 5,000 내지 10,000 rpm 으로 원심분리하여 회수한 침전물을 증류수로 3회 세척 후 원심분리하여, 침전물로써 반응액을 수득할 수 있다. After dissolving an extract containing dydazine or dydzein in 5 to 10 times, preferably about 10 times, ionized water, sterilizing at 121 ° C. for 30 minutes, cooling to 30 ° C., and comparing the pre-cultured microorganisms to the amount of liquid After inoculating 5 to 10% and incubating at 30 ° C. for 2 to 5 days, the precipitate recovered by centrifugation at 5,000 to 10,000 rpm was washed three times with distilled water and then centrifuged to obtain a reaction solution as a precipitate.
미생물은 다이드진에서 당 부분을 제거하여 다이드제인을 생성하고 여기에 수산화기를 전달하여 3`,4`,7-트리히드록시 이소플라본을 제조할 수 있다. 3`,4`,7-트리히드록시 이소플라본을 제조한 후, 반응액을 감압농축하여 용매를 제거하고, 잔사에 알코올을 가하여 1 내지 5회 교반시킨 후, 침전된 염들을 여과를 통하여 제거하고, 여과된 여액을 감압농축하여 조 생성물을 수득하고, 상기 수득한 조 생성물을 실리카겔 컬럼 크로마토그래피(클로로포름: 메탄올= 8:1 내지 4:1)로 분리하여 일정량의 3`,4`,7-트리히드록시 이소플라본을 수득할 수 있다. The microorganism may remove the sugar portion from the dydazine to produce dydzein and deliver the hydroxyl group to it to produce 3 ′, 4 ′, 7-trihydroxy isoflavones. After preparing 3`, 4`, 7-trihydroxy isoflavone, the reaction solution was concentrated under reduced pressure to remove the solvent, and the residue was stirred 1 to 5 times by adding alcohol to the residue, and then the precipitated salts were removed by filtration. The filtrate was concentrated under reduced pressure to give a crude product. The crude product was separated by silica gel column chromatography (chloroform: methanol = 8: 1 to 4: 1) to obtain a predetermined amount of 3 ′, 4 ′, 7 -Trihydroxy isoflavones can be obtained.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.
1-1. 1-1. 트리히드록시Trihydroxy 이소플라본의 제조 Preparation of Isoflavones
(1) 대두 추출물의 제조(1) Preparation of Soybean Extract
대두 2 ㎏에 각각 헥산 6 ℓ를 넣고, 상온에서 3회 교반 추출하여 탈지시킨 다음, 탈지된 대두 1 kg에 80 % 메탄올 4 ℓ를 넣고, 3회 환류 추출한 후, 15 ℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하고, 분리된 여액을 감압농축하여 얻은 엑기스를 물에 현탁한 후, 에테르 1 ℓ로 5회 추출하여 색소를 제거하고, 수층을 1-부탄올 500 ㎖로 3회 추출하였다. 이로부터 얻은 총 1-부탄올층을 감압농축하여 1-부탄올 엑기스를 얻고, 이를 소량의 메탄올에 녹인 다음, 대량의 에틸아세테이트에 추가하여, 생성된 침전물을 건조함으로써, 대두 추출물 300 g을 수득하였다.6 kg of hexane was added to 2 kg of soybean, and stirred and extracted three times at room temperature. Then, 4 l of 80% methanol was added to 1 kg of degreased soybean, and refluxed three times. Thereafter, the residue and the filtrate were separated by filtration through a filter cloth and centrifugation. The separated filtrate was concentrated under reduced pressure, and the resulting extract was suspended in water. The filtrate was extracted 5 times with 1 L of ether to remove the pigment. And extracted three times with 500 ml of butanol. The total 1-butanol layer thus obtained was concentrated under reduced pressure to obtain 1-butanol extract, which was dissolved in a small amount of methanol, and then added to a large amount of ethyl acetate, and the resulting precipitate was dried to obtain 300 g of soybean extract.
(2) 미생물을 이용한 3',4',7-트리히드록시 이소플라본의 제조(2) Preparation of 3 ', 4', 7-trihydroxy isoflavones using microorganisms
상기 (1)에서 수득한 대두 추출물 10 g을 100 ㎖의 이온수에 용해시키고, 121 ℃에서 30분간 멸균하여 30 ℃로 냉각한 후, 미리 배양된 아스퍼질러스 니거(Aspergillus niger , KCCM 11885)를 액체량 대비 5~10 %로 접종하여 30 ℃에서 7일 동안 배양시킨 후, 박층 크로마토그래피로 기질의 소거율을 확인하여 기질이 완전히 소실되면 반응을 종료시켰다. 이 배양액을 5,000 내지 10,000 rpm으로 원심분리하여 회수한 침전물을 증류수로 3회 세척 후 원심분리하여 침전물로써 반응액을 얻은 다음, 상기 침전물에 에탄올(200㎖)을 가해 교반시킨 후(3회), 침전된 염들을 여과를 통해 제거하였다. 그 다음, 여과된 여액을 감압농축하여 조 생성물을 수득하였다. 이후 상기 수득된 조 생성물을 실리카겔 컬럼 크로마토그래피(클로로포름: 메탄올 = 8:1 ~ 4:1)로 분리하여 3',4',7-트리히드록시 이소플라본 0.12 g을 수득하였다.10 g of the soybean extract obtained in the above (1) was dissolved in 100 ml of ionized water, sterilized at 121 ° C. for 30 minutes, cooled to 30 ° C., and then incubated with Aspergillus niger ( Aspergillus). niger , KCCM 11885) was inoculated with 5-10% of the liquid amount and incubated for 7 days at 30 ° C., and then the substrate was completely removed by thin layer chromatography to terminate the reaction. The precipitate obtained by centrifuging the culture solution at 5,000 to 10,000 rpm was washed three times with distilled water, followed by centrifugation to obtain a reaction solution as a precipitate. The precipitate was added with ethanol (200 ml) and stirred (3 times), Precipitated salts were removed by filtration. The filtrate was then concentrated under reduced pressure to give the crude product. The crude product obtained was then separated by silica gel column chromatography (chloroform: methanol = 8: 1-4: 1) to give 0.12 g of 3 ', 4', 7-trihydroxy isoflavone.
1-2. 1-2. 백굴채White oyster 추출물의 제조 Preparation of extract
백굴채 2 ㎏를 분쇄하여 열수 4 ℓ를 넣고 3회 환류 추출한 후, 15 ℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하고, 분무 건조하여 백굴채 추출물 200 g을 수득하였다.2 kg of white oysters were ground, 4 L of hot water was added, and the mixture was extracted under reflux three times, followed by immersion at 15 ° C. for 1 day. Thereafter, the residue and the filtrate were separated through filter cloth filtration and centrifugation, followed by spray drying to obtain 200 g of white bran extract.
1-3.1-3. 백굴채White oyster 추출물 및 Extract and 트리히드록시Trihydroxy 이소플라본의 제조 Preparation of Isoflavones
상기 방법으로 제조된 백굴채 추출물 및 3',4',7-트리히드록시 이소플라본을 60: 1 의 비율로 혼합한 후, 즉 백굴채추출물 6g 과 트리히드록시 이소플라본 0.1g 의 비율로 혼합한 후, 추출물 총 중량 대비 10배의 70% 에탄올 수용액으로 재추출하고 원심분리와 여과포 여과를 통해 잔사와 여액을 분리하였다. 그 후 감압 농축하여 백굴채 추출물 및 3',4',7-트리히드록시 이소플라본의 혼합물를 제조하였다. White bran extract prepared by the above method and 3 ', 4', 7-trihydroxy isoflavones were mixed at a ratio of 60: 1, that is, 6 grams of white buckwheat extract and 0.1 g of trihydroxy isoflavones were mixed. After that, the extract was re-extracted with 70% ethanol aqueous solution 10 times the total weight of the extract, and the residue and the filtrate were separated by centrifugation and filter cloth filtration. Then, the mixture was concentrated under reduced pressure to prepare a mixture of Baekchulchae extract and 3 ', 4', 7-trihydroxy isoflavone.
세포 독성 시험Cytotoxicity test
실시예 1-3에서 얻어진 백굴채 추출물 및 트리히드록시 이소플라본 혼합물에 대하여, 실시예 1-2에서 얻은 백굴채 추출물을 비교실험예로 사용하여, 쥐의 색소세포에서 세포 독성 정도를 확인하였다.About the white oyster extract obtained in Example 1-3 and the trihydroxy isoflavone mixture, the white oyster extract obtained in Example 1-2 was used as a comparative experiment, and the degree of cytotoxicity was confirmed in the pigment cells of rats.
DMEM(Dulbeccos modified Eagles media)에 10% 우태반 혈청, 100nM 2-O-테트라데카노일포르빌(tetradecanoyphorbol)-13-아테이트, 1nM 콜레라 독소(cholera toxin)을 첨가한 배지에서, C57BL/6 마우스 유래의 쥐의 색소세포(Mel-Ab cell)(Dooley, T.P. et al, Skin pharmacol, 7:188-200)를 37℃, 5% CO2의 조건에서 배양하였다. 배양된 Mel-Ab세포를 0.25% 트립신-EDTA로 떼어내고, 24-웰 플레이트에 105 세포/웰(cells/well)의 농도로 세포를 배양한 후, 백굴채 추출물 및 트리히드록시 이소플라본 혼합물 및 백굴채 추출물 각각의 샘플을 처리하고 24시간 동안 배양한 후, 인산염 완충용액(pH 7.2)으로 세척하여 0.1% 크리스탈 바이올렛(crystal violet. 시그마), 10% 에탄올을 이용하여 5분 동안 상온에서 염색하였다. 염색되지 않은 크리스탈 바이올렛을 완전히 제거 한 다음, 인산염 완충용액(pH 7.2)으로 3회 세척하였다. 그 후, 염색된 세포로부터 크리스탈 바이올렛을 추출하기 위하여 95% 에탄올을 1시간 동안 상온에서 처리하였으며, 추출액을 PerkinElmer 사의 Lambda 25 spectrophotometer 540 nm 파장에서 측정하여 얻은 흡광도를 통하여 세포의 생존율을 비교하였다. 세포의 생존율은 하기 수학식 1에 따라 계산하였으며, 실험 결과는 하기 표 1과 같았다.C57BL / 6 mice in medium supplemented with 10% fetal placental serum, 100 nM 2-O-tetradecanoylphorbol-13-ate, 1 nM cholera toxin in Dulbeccos modified Eagles media (DMEM) Derived mouse pigment cells (Mel-Ab cells) (Dooley, TP et al, Skin pharmacol, 7: 188-200) were incubated at 37 ℃, 5% CO 2 conditions. The cultured Mel-Ab cells were detached with 0.25% trypsin-EDTA, incubated at a concentration of 10 5 cells / well in 24-well plates, and then the oleander extract and trihydroxy isoflavone mixtures. After treatment with each sample of Baekchulchae extract and incubated for 24 hours, washed with phosphate buffer (pH 7.2) and stained at room temperature for 5 minutes using 0.1% crystal violet (sigma), 10% ethanol It was. The undyed crystal violet was completely removed and washed three times with phosphate buffer (pH 7.2). Thereafter, 95% ethanol was treated at room temperature for 1 hour to extract crystal violet from the stained cells, and the viability of the cells was compared through the absorbance obtained by measuring the extract at a wavelength of 540 nm of Lambda 25 spectrophotometer manufactured by PerkinElmer. The survival rate of the cells was calculated according to Equation 1 below, and the experimental results are shown in Table 1 below.
A: 샘플 첨가한 흡광도A: absorbance added to the sample
B: 샘플 첨가하지 않은 흡광도B: Absorbance Without Sample Addition
3',4',7-트리히드록시 이소플라본의 혼합물
(실시예 1-3)White bran extract and
Mixture of 3 ', 4', 7-trihydroxy isoflavones
(Example 1-3)
상기 표 1과 같이, 본 발명에 따른 백굴채 추출물 및 3',4',7-트리히드록시 이소플라본의 혼합물은 백굴채 추출물 단독의 경우에 비하여, 피부 세포의 독성을 현격히 감소시키는 것으로 확인되었다.As shown in Table 1, the mixture of Baekjakchae extract and 3 ', 4', 7-trihydroxy isoflavone according to the present invention was found to significantly reduce the toxicity of skin cells, compared to Baekjakchae extract alone. .
멜라닌 생성 억제효과 측정Melanin production inhibitory effect measurement
실시예 1-3에서 얻어진 백굴채 추출물 및 트리히드록시 이소플라본의 혼합물에 대하여, 실시예 1-2에서 얻어진 백굴채 추출물과 실시예 1-1에서 얻어진 3',4',7-트리히드록시 이소플라본을 비교실험예로 사용하여, 쥐의 색소세포를 이용하여, 멜라닌 생성 억제효과를 측정하였다.Regarding the mixture of the baekgulchae extract and trihydroxy isoflavone obtained in Example 1-3, the baekbaekchae extract obtained in Example 1-2 and the 3 ', 4', 7-trihydroxy obtained in Example 1-1 Using isoflavones as a comparative experimental example, melanin production inhibitory effect was measured using pigment cells of rats.
C57BL/6 마우스 유래의 쥐의 색소세포(Mel-Ab cell)(Dooley, T.P. et al, Skin pharmacol, 7:188-200)를 DMEM(Dulbeccos modified Eagles media)에 10% 우태반 혈청, 100nM 2-O-테트라데카노일포르빌(tetradecanoyphorbol)-13-아테이트, 1nM 콜레라 독소(cholera toxin)을 첨가한 배지에서 37℃, 5% CO2의 조건에서 배양하였다. 배양된 Mel-Ab세포를 0.25% 트립신-EDTA로 떼어내고, 24-웰 플레이트에 105 세포/웰(cells/well)의 농도로 세포를 배양하고 이틀째부터 3일 연속으로 10ppm의 각 시험물질로 하이드로퀴논, 백굴채 추출물, 3',4',7-트리히드록시 이소플라본 및 이의 혼합물을 가하여 배양하였다. 이때, 상기 하이드로퀴논은 양성대조군으로 사용하였다. 그 다음 배양액을 제거하고, PBS로 세척한 후, 1N 수산화나트륨으로 세포를 녹여 400nm에서 흡광도를 측정한 후, 하기 수학식 2에 따라 멜라닌 생성 억제율을 계산하여(Dooley의 방법) 그 결과를 하기 표 2에 나타내었다. Mel-Ab cells derived from C57BL / 6 mice (Dooley, TP et al, Skin pharmacol, 7: 188-200) in DMEM (Dulbeccos modified Eagles media) 10% fetal placental serum, 100 nM 2- Incubated at 37 ° C. and 5% CO 2 in a medium to which O-tetradecanoylphorbol-13-ate and 1 nM cholera toxin were added. The cultured Mel-Ab cells were detached with 0.25% trypsin-EDTA, incubated at a concentration of 10 5 cells / well in 24-well plates, and 10 ppm each test substance for 3 consecutive days from the second day. Hydroquinone, white bran extract, 3 ', 4', 7-trihydroxy isoflavone and mixtures thereof were added and incubated. At this time, the hydroquinone was used as a positive control group. Then, the culture solution was removed, washed with PBS, dissolved in 1N sodium hydroxide, and measured for absorbance at 400 nm. Then, the melanin production inhibition rate was calculated according to Equation 2 below (Dooley's method). 2 is shown.
(실시예 1-2)White bran extract
(Example 1-2)
20.3
(실시예 1-1)3 ', 4', 7-trihydroxyisoflavone
(Example 1-1)
3',4',7-트리히드록시이소플라본 혼합물
(실시예 1-3)White bran extract and
3 ', 4', 7-trihydroxyisoflavone mixture
(Example 1-3)
상기 표 2에 나타낸 바와 같이, 본 발명에 따른 백굴채 추출물 및 3',4',7-트리히드록시 이소플라본의 혼합물은 하이드로퀴논, 백굴채 추출물 단독 및 3',4',7-트리히드록시이소플라본 단독의 경우와 비교하여 현저하게 우수한 멜라닌 생성 억제율을 보이는 것을 확인할 수 있었다. As shown in Table 2, the mixture of Baekchulchae extract and 3 ', 4', 7-trihydroxy isoflavone according to the present invention is hydroquinone, Baekchulchae extract alone and 3 ', 4', 7-trihydride It was confirmed that the melanin production inhibition rate was remarkably excellent compared to the case of oxyisoflavones alone.
인체 피부에 대한 미백 효과 시험Test for whitening effect on human skin
실시예 1-3에 의해 제조된 백굴채 추출물 및 3',4',7-트리히드록시 이소플라본의 혼합물이 인체 피부에 대한 미백 효과를 가지는지 확인하기 위한 실험을 수행하였다.An experiment was conducted to determine whether the mixture of Baekchulchae extract prepared in Example 1-3 and 3 ', 4', 7-trihydroxy isoflavone had a whitening effect on human skin.
먼저, 건강한 12명의 남자를 대상으로 피검자의 상박 부위에 직경 1.5㎝의 구멍이 뚫린 불투명 테이프를 부착한 뒤, 각 피검자의 최소 홍반량(Minimal Erythema Dose)의 1.5 ~ 2배 정도의 자외선(UVB)을 조사하여 피부의 흑화를 유도하였다.First, a opaque tape with a diameter of 1.5 cm was attached to the upper arm of 12 healthy men, and then 1.5 ~ 2 times of ultraviolet light (UVB) of the minimum Erythema Dose of each subject. Was irradiated to induce skin blackening.
상기 자외선 조사 후 시험물질로 상기 실시예 1-3로부터 수득한 3',4',7-트리히드록시 이소플라본 및 백굴채 추출물 혼합물을 각 1% (용매는 1,3-부틸렌그리콜:에탄올 = 7:3), 하이드로퀴논(양성 대조군) 각 1%, 용매(vehicle)(음성 대조군) 1% 만을 바르고, 한 곳은 아무 것도 바르지 않고 10 주 동안 상태변화를 관찰했다. 1주 단위로 피부의 색깔을 색차계 CR2002(미놀타 사,일본)로 측정하였다. After the ultraviolet irradiation, 1% of 3 ', 4', 7-trihydroxy isoflavone and white oyster extract extract obtained from Example 1-3 were used as test materials. (The solvent is 1,3-butylene glycol: ethanol. = 7: 3), only 1% of each hydroquinone (positive control) and 1% of a solvent (negative control) were applied, and one state was observed for 10 weeks without applying anything. Skin color was measured on a weekly basis with a colorimeter CR2002 (Minolta, Japan).
그 다음 상기 각 시험물질의 도포 개시시점과 도포 완료시점에서의 피부색의 차이(△L*)를 하기 수학식 3에 따라 계산하고, 이를 하기 표 3에 나타내었다. 미백 효과는 시료 도포 부위와 대조군 부위의 △L*의 비교로 판정하는데, △L*값이 2 정도일 경우는 침착된 색소의 미백화가 뚜렷한 경우이고, 1.5정도 이상이면 미백효과가 있다고 판정할 수 있다. Then, the difference in skin color (ΔL *) between the start point of application and the end point of application of each test substance was calculated according to Equation 3 below, which is shown in Table 3 below. The whitening effect is determined by comparing ΔL * between the sample application site and the control site. When the ΔL * value is about 2, the whitening effect of the deposited pigment is clear, and when it is about 1.5 or more, the whitening effect may be determined. .
3',4',7-트리히드록시 이소플라본 혼합물
(실시예 1-3)White bran extract and
3 ', 4', 7-trihydroxy isoflavone mixture
(Example 1-3)
상기 표 3에 나타낸 바와 같이, 본 발명에 따른 백굴채 추출물 및 3',4',7-트리히드록시 이소플라본의 혼합물은 하이드로퀴논보다 우수한 피부색 밝기 정도를 나타냈다. 이는 백굴채 추출물 및 3',4',7-트리히드록시 이소플라본의 혼합물이 피부 세포의 사멸을 억제하고, 자외선에 의해 생성된 색소 침착을 개선하여 피부색을 밝게 하기 때문이다.As shown in Table 3, the mixture of Baekchulchae extract and 3 ', 4', 7-trihydroxy isoflavone according to the present invention showed a better skin color brightness than hydroquinone. This is because the mixture of Baekchulchae extract and 3 ', 4', 7-trihydroxy isoflavones inhibits the death of skin cells and improves pigmentation produced by ultraviolet light to brighten skin color.
이하, 상기 화장료 조성물의 제형예를 설명하나, 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, the formulation examples of the cosmetic composition, but not intended to limit the present invention is intended to be described in detail only.
(실시예 1-3)Mixture of white bran extract and 3 ', 4', 7-trihydroxy isoflavone
(Example 1-3)
(실시예 1-3) Mixture of white bran extract and 3 ', 4', 7-trihydroxy isoflavone
(Example 1-3)
(실시예 1-3) Mixture of white bran extract and 3 ', 4', 7-trihydroxy isoflavone
(Example 1-3)
(실시예 1-3) Mixture of white bran extract and 3 ', 4', 7-trihydroxy isoflavone
(Example 1-3)
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.
While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. something to do. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (13)
콩과식물을 탈지하는 단계;
탈지된 콩과식물을 용매에 넣고 추출물을 얻는 단계; 및
상기 추출물에 미생물을 접종하고 배양하는 단계를 포함하는, 피부 미백용 조성물의 제조방법.
The method of claim 8, wherein the trihydroxy isoflavone is prepared.
Degreasing legumes;
Putting the defatted legumes in a solvent to obtain an extract; And
Inoculating and culturing the microorganisms to the extract, method of producing a composition for skin whitening.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110111810A KR20130047040A (en) | 2011-10-31 | 2011-10-31 | Composition for skin whitening containing chelidonium majus extracts and trihydroxyisoflavones |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110111810A KR20130047040A (en) | 2011-10-31 | 2011-10-31 | Composition for skin whitening containing chelidonium majus extracts and trihydroxyisoflavones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20130047040A true KR20130047040A (en) | 2013-05-08 |
Family
ID=48658605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020110111810A KR20130047040A (en) | 2011-10-31 | 2011-10-31 | Composition for skin whitening containing chelidonium majus extracts and trihydroxyisoflavones |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20130047040A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016175589A3 (en) * | 2015-04-30 | 2016-12-22 | 안국약품 주식회사 | Pharmaceutical composition for preventing or treating respiratory diseases, containing extract of mixed herbal medicines |
| KR20230046327A (en) * | 2021-09-28 | 2023-04-06 | 메디허브바이오 주식회사 | Composition for skin whitening comprising mixture of fermented ginseng leaf extract and Miscanthus sinensis extract as effective component |
| KR20230046326A (en) * | 2021-09-28 | 2023-04-06 | 메디허브바이오 주식회사 | Composition for skin whitening comprising mixture of Chelidonium majus var. asiaticum extract, fermented ginseng leaf extract and Miscanthus sinensis extract as effective component |
-
2011
- 2011-10-31 KR KR1020110111810A patent/KR20130047040A/en active Search and Examination
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016175589A3 (en) * | 2015-04-30 | 2016-12-22 | 안국약품 주식회사 | Pharmaceutical composition for preventing or treating respiratory diseases, containing extract of mixed herbal medicines |
| KR20230046327A (en) * | 2021-09-28 | 2023-04-06 | 메디허브바이오 주식회사 | Composition for skin whitening comprising mixture of fermented ginseng leaf extract and Miscanthus sinensis extract as effective component |
| KR20230046326A (en) * | 2021-09-28 | 2023-04-06 | 메디허브바이오 주식회사 | Composition for skin whitening comprising mixture of Chelidonium majus var. asiaticum extract, fermented ginseng leaf extract and Miscanthus sinensis extract as effective component |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101326690B1 (en) | Cosmetic composition for skin whitening containing melanin biosynthesis inhibitors from Korean ginseng | |
| KR101492074B1 (en) | Compositions containing an extract of hydrangea macrophylla for. otaksa for skin whitening | |
| EP2203151A1 (en) | Use of melanin biosynthesis inhibitors from korean ginseng and the cosmetic composition containing thereof for skin whitening | |
| KR20110108687A (en) | Skin whitening agent containing extracts of natural materials and composition of cosmetic | |
| KR20180004367A (en) | Cosmetic composition with the extract of Aurea Helianthus for skin-whitening | |
| CN111053716A (en) | Application of Fuzhuan tea extract in preparation of skin conditioning product | |
| CN111201012A (en) | Cosmetic composition for skin whitening and wrinkle improvement comprising centella asiatica adventitious root extract as active ingredient | |
| KR20200138870A (en) | Composition for preventing or improving skin aging comprising an extract of rhodiola sachalinesis fermented by bovista plumbea | |
| KR20170048904A (en) | Cosmetic compositions for skin whitening containing costunolide from natural extracts | |
| KR102343112B1 (en) | Anti-aging composition comprising functional peptides, amino acids, callus extract and fermented materials | |
| KR20130047040A (en) | Composition for skin whitening containing chelidonium majus extracts and trihydroxyisoflavones | |
| KR101688453B1 (en) | Cosmetic composition for skin whitening, reducing skin pore size and secreting sebum | |
| KR101863297B1 (en) | Composition for preventing or improving skin wrinkle comprising chlorogenic acid and rutin compound as active ingredient | |
| KR102002997B1 (en) | Cosmetic composition including taxifolin glucosides and extracting method of paeonia lactiflora extracts | |
| KR101854766B1 (en) | Skin whitening complex containing trihydroxyisoflavone and glycyrrhiza uralensis extracts | |
| KR20070021856A (en) | Cosmetic composition for skin whitening effect comprising kaempferol | |
| KR20160081445A (en) | A composition for antioxidating, whitening and improving wrinkle comprising extracts of false indigo | |
| KR101921903B1 (en) | Composition for antioxidation or whitening containing 21-O-angeloyltheasapogenol E3 from green tea seed | |
| KR102057376B1 (en) | Composition for skin whitening comprising extract of stichopus japonicas red | |
| KR102121457B1 (en) | Cosmetic composition comprising the extract of fermented Sophora Japonica Fruits for skin anti-wrinkle effect and producing method thereof | |
| KR101176525B1 (en) | Cosmetic Composition Comprising Acer tegmentosum Maxim as Active Ingredient | |
| KR101273027B1 (en) | Composition for inhibiting sebum secretion and anti-obesity comprising kaempferol | |
| KR101768162B1 (en) | Skin whitening complex containing trihydroxyisoflavone and morus alba leaf extracts | |
| KR100614467B1 (en) | Cosmetic composition comprising the extract mixture of euphorbia helioscopia l., paeonia suffruticosa andr. and aloe vera l. having inhibition activity of melanin synthesis | |
| KR20140071716A (en) | Cosmetic composition comprising the extract of Akebia quinata as active ingredi ent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment |